// startup autopsy
Aldexa Therapeutics
The eye therapeutics startup that ran out of vision and capital simultaneously
marketfitSilent Shutdown
Quiet closure with no public announcement · Fatal mistake: Aldexa Therapeutics failed to reach a clinical proof-of-concept milestone with insufficient capital to sustain the long development timelines inherent to ophthalmic drug development.
Key Events Timeline
FOUNDING
Aldexa Therapeutics founded to develop novel ophthalmic therapeutics, targeting the significant unmet medical need in eye disease treatment.
PRODUCT LAUNCH
Early preclinical work progresses on lead ophthalmic compound. Company secures initial seed funding to advance toward IND-enabling studies.
PRODUCT LAUNCH
Clinical development timelines extend beyond initial projections. Funding runway grows shorter relative to remaining development milestones needed for Series A qualification.
FUNDING
Final funding secured bringing total to $4.8M. Despite nearly a decade of work, clinical proof-of-concept data remains elusive, making Series A fundraising challenging.
SHUTDOWN
Aldexa Therapeutics closes operations after failing to secure additional investment. A decade of ophthalmic drug development ends without a clinical asset advanced enough to attract acquirers or partners.